Discontinuing lipid-lowering agents

被引:2
|
作者
Davis, George F.
机构
关键词
D O I
10.1089/jpm.2006.9.619
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
引用
收藏
页码:619 / 619
页数:1
相关论文
共 50 条
  • [31] Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
    Alfonsi, Jeffrey E.
    Hegele, Robert A.
    Gryn, Steven E.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (05)
  • [32] Differential effects of lipid-lowering agents on human cholinesterases
    Darvesh, S
    Martin, E
    Walsh, R
    Rockwood, K
    CLINICAL BIOCHEMISTRY, 2004, 37 (01) : 42 - 49
  • [33] Myotoxicity of Lipid-Lowering Agents in a Teenager With MELAS Mutation
    Tay, Stacey K. H.
    DiMauro, Salvatore
    Pang, Aileen Y. W.
    Lai, Poh-San
    Yap, Hui-Kim
    PEDIATRIC NEUROLOGY, 2008, 39 (06) : 426 - 428
  • [34] Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction
    Amarenco, P
    NEUROLOGY, 2001, 57 (05) : S35 - S44
  • [35] Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
    Jeffrey E. Alfonsi
    Robert A. Hegele
    Steven E. Gryn
    Current Atherosclerosis Reports, 2016, 18
  • [36] Lipid-lowering agents and fibrinolysis:: lack of effect in vitro
    Elzaher, SM
    Pallister, CJ
    Dunn, CDR
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2001, 58 (04) : 244 - 246
  • [37] Role of lipid-lowering agents in the management of diabetic retinopathy
    Ioannidou, Estelle
    Tseriotis, Vasilis-Spyridon
    Tziomalos, Konstantinos
    WORLD JOURNAL OF DIABETES, 2017, 8 (01) : 1 - 6
  • [39] IMPROVEMENT OF COMPLIANCE WITH LIPID-LOWERING AGENTS IMPROVEMENT OF THE COMPLIANCE OF LIPID-LOWERING MEDICATION. CONTROLLED STUDY IN COMMUNITY PHARMACY
    Andres Iglesias, J. Carlos
    Andres Rodriguez, N. Floro
    Fornos Perez, Jose A.
    FARMACEUTICOS COMUNITARIOS, 2009, 1 (03): : 92 - 98
  • [40] Synthetic statins: More data on newer lipid-lowering agents
    Wierzbicki, AS
    CURRENT MEDICAL RESEARCH AND OPINION, 2001, 17 (01) : 74 - 77